What question did this study set out to answer?

The aim is to explore challenges in using aggregation-induced emission (AIE) agents and their combination with nanocarriers for cancer treatment.

April 12, 2026Nanoscale0 citations

Nanocarrier-empowered aggregation-induced luminescence and its therapeutic promise in oncology

View Full Paper

YLY. X. LiTiangong University LGLin GengTiangong University YHYilin HanBeijing Institute of Technology

Key Points

The aim is to explore challenges in using aggregation-induced emission (AIE) agents and their combination with nanocarriers for cancer treatment.
Systematic review of existing literature on AIEgen applications and challenges.
Analysis of biocompatibility and safety issues associated with AIEgens in vivo.
Evaluation of strategies to improve AIEgen effectiveness using nanocarrier technology.
Identified significant limitations in current AIEgen applications for oncology.
Proposed solutions involving nanocarriers to enhance biocompatibility and safety.
Recommended strategies indicate promising pathways for therapeutic advancements.

Abstract

This article focused on the key bottlenecks in the in vivo applications of AIEgens and systematically reviewed strategies for combining nanocarriers with them to address issues such as biocompatibility and biosafety.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Li et al. (Thu,) studied this question.

synapsesocial.com/papers/69db37254fe01fead37c51bd https://doi.org/https://doi.org/10.1039/d5nr04932f

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper